# A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Source: https://onco.cc/trials/nct05475925/  
OnCo record `nct05475925` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DR-01 in peripheral T-cell lymphomas, run by Dren Bio, now recruiting.

## Summary

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas is a phase 1/2 interventional study registered as NCT05475925 by Dren Bio, with 200 participants planned, started 2022-07-13 and due to reach its primary completion in 2026-12. Interventions recorded: DR-01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05475925
- Phase: 1/2
- Setting: A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Sponsor: Dren Bio
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05475925: https://clinicaltrials.gov/study/NCT05475925

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [DR-01](https://onco.cc/drugs/dr-01/)

---
JSON: https://onco.cc/api/v1/entities/nct05475925.json